Has China crossed an ethical red line?

China’s recent biotech research has shocked many observers for apparently crossing ethical boundaries.


 


China is investing massively in biomedical research. Earlier this year, Chinese researchers published the results of an experiment in editing the genes of human embryos. The researchers may have failed in their attempts to modify a gene that causes beta-thalassemia, but was it a line than should never have been crossed?

 

It is a small step from trying to eliminate a blood disorder to choosing eye colour or intelligence.

 

But Chinese biomedical research is a little like an oil tanker – hard to slow and virtually impossible to stop. In 2013, the State invested around £120 billion in “the development of scientific research and experimentation.”

 

Confucius believed that someone only becomes a person after they are born so embryo experimentation doesn’t necessarily stir as many negative emotions in China. Despite this, the State does have a moratorium on experiments involving embryos that are older than 14 days.

 

That’s the trouble with ethics – it all boils down to personal beliefs – but then what doesn’t?


LinkedIn

     Email

Share on LinkedIn

    

Share via Email

                                 

                                    +21,000 STUDENTS        +9,400 COMPANIES          +100 COUNTRIES

 

Novartis logo                        NHS logo                        Takeda logo                        Roche logo                        DHL logo                        Baxter logo                        King's College logo                        US AID logo                        Novo Nordisk logo                           Grunenthal logo                           Wellcome logo                           Ipsen logo                           BTG logo                           
-->